Revolutionizing Ventilation with Airflow1000

BreathIN is pioneering respiratory care through groundbreaking implantable ventilator technology, designed to fundamentally transform the lives of ventilator-dependent patients.

Adi Shalev,
CEO

Over 10 years in medical device management, expertise in startups and international corporations

Omri Naveh,
Co-Founder

Proven track record leading products from concept through FDA approval and mass production

Dr. Elias Hellou,
Clinical Specialist
& Co-Founder

Expert in internal medicine and invasive cardiology

Prof. Fahed Hakim,
Co-Founder

Pediatric and pulmonary specialist, Medical Director at E.M.M.S. Hospital, Nazareth

The Problem

Mechanical ventilation is essential for patients with degenerative diseases, cervical trauma, or prolonged respiratory failure.

Current external ventilators significantly impact patient quality of life, causing severe complications, including loss of speech, repeated hospitalizations, restricted mobility, and progressive muscle weakness.

Additionally, these traditional solutions carry high financial burdens, averaging ~$450,000 per patient over three years.

Our Solution: Airflow1000

Airflow1000 is an innovative Negative Pressure Implantable Ventilator that closely mimics the body's natural breathing mechanism.

Enhanced Quality of Life

Liberates patients from external ventilators, restoring mobility and significantly improving life quality.

Infection Reduction

Minimally invasive implantation eliminates the need for tracheostomy, reducing infection risks.

Cost-Efficiency

Cuts ventilation costs by up to 55%, saving substantial healthcare expenditures.

Unique Operational Modes

Adaptive autonomic regulation with specialized "Speaking" and "Coughing" modes, enabling natural interaction.

Market Opportunity

Over 500,000 potential patients in the U.S. alone

Each patient presents a ~$450k three-year expenditure; Airflow1000 significantly reduces these costs

Intellectual Property

US Patent No. 15/572831: Granted

EU Patent No. EP3302396: Granted

PCT/IL2024/050051: Filed Jan 14, 2024

Investment Opportunity

BreathIN offers investors the chance to significantly impact healthcare outcomes, improve patient lives, and capitalize on a sizable, growing market with a patented and cost-effective solution.

Let’s Talk

Adi Shalev, CEO

Phone

+972 54 330 2137

Email

adi@breathin-ltd.com